24-month Phase I follow-up data show positive outcomes are maintained High levels of investigator and patient satisfaction, excellent safety profileOngoing registrational…
October 09, 2025 02:00 ET | Source: Ariceum Therapeutics Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study…
Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio’s Revio system, powering one of the largest studies…
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and…
COMMACK, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned…
Clearing a Major Technological Hurdle, Checkerspot & Huvepharma Ready to Scale Production of the Novel, Direct Analog for Human Milk…
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article…
GAINESVILLE, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- NeXtGen Biologics announces the issuance of a third U.S. patent, US12311079, on…
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES…
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical…